Uncategorized

Should health systems see their investment income decline, cash on hand could fall nearly 7% from the first half of 2024, hindering health systems’ ability to weather other headwinds.

The draft budget would slash FDA’s budget authority, if approved by Congress.

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down operations given “the current state of the public equity market.”

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

The program is among those targeted for closure in a budget draft for the HHS.

Losing the FDA’s senior negotiators would slow the renewal of the user fee programs “considerably,” according to policy and regulatory expert Steven Grossman.

Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public markets “in due course.”

Industry representatives will still be allowed at these meetings, but they will no longer have a spot on the advisory committee.

Like they say about the weather in Iceland, if you don’t like an action taken by the new administration, wait five minutes; it’ll probably change. The markets, it seems, don’t react kindly to that kind of policymaking.

An OMB document proposes to cut the HHS budget by roughly one-third as well as eliminate several divisions and programs.